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Abstract
Background: Lethal toxin (LT), the major virulence factor produced by Bacillus anthracis, has been shown to suppress the
immune system, which is beneficial to the establishment of B. anthracis infections. It has been suggested that the
suppression of MEK/MAPK signaling pathways of leukocytes contributes to LT-mediated immunosuppressive effects.
However, the involvement of MAPK independent pathways has not been clearly elucidated; nor has the crucial role played
by LT in the early stages of infection. Determining whether LT exerts any pathological effects before being enriched to an
MEK inhibitory level is an important next step in the furtherance of this field.
Methodology/Principal Findings: Using a cell culture model, we determined that low doses of LT inhibited phagocytosis of
macrophages, without influencing MAPK pathways. Consistent low doses of LT significantly suppressed bacterial clearance
and enhanced the mortality of mice with bacteremia, without suppressing the MEK1 of splenic and peripheral blood
mononuclear cells.
Conclusion/Significance: These results suggest that LT suppresses the phagocytes in a dose range lower than that required
to suppress MEK1 in the early stages of infection.
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Introduction
Anthrax refers to diseases caused by infection with the Gram-
positive bacterium Bacillus anthracis. The bacteria replicates to very
high numbers in the blood, leading to the death of the host.
Because the bacteria spread extensively without an evident
immune response, it has been suggested that the pathogen impairs
the immune system of the host. Recent studies have shown that
lethal toxin (LT), the major virulence factor of Bacillus anthracis [1–
3], strongly contributes to this intervention through pleiotropic
action on various cells of the host immune system [4–5]. Lethal
toxin isogenic mutant bacteria lacks single toxin components and
is therefore greatly attenuated [6–7]. Lethal toxin is a bipartite
protein complex comprising protective antigen (PA) and the lethal
factor (LF), which functionally inactivates the mitogen activated
protein kinase kinases (MAPKKs/MEKs) through metalloprotease
activity of LF [8–10]. Mitogen activated protein kinases (MAPKs)
are downstream effectors of MEKs, which were divided into the
extracellular-regulated kinase (ERK, p42/44), p38, and c-Jun
amino terminal protein kinase (JNK) subgroups. These have been
implicated in multiple cellular events such as proliferation,
survival, differentiation and inflammation [11]. Lethal toxin
inhibits phagocytic function through the suppression of MEK-
mediated generation of bactericidal superoxide and MEK-
mediated survival of macrophage cells [12–13]. Whether or not
LT suppresses macrophage function through a MEK/MAPK
independent pathway, however, remains unclear.
Some evidences have implied that LT might play an inhibitory
role in phagocytic function of phagocytes at low doses without
perturbing the MEK/MAPK pathways. Lethal toxin was shown
to inhibit actin dynamics without influencing the MEK1 pathway;
the inhibition of actin dynamics blocks the migration of
neutrophil and Listeria-driven actin motility [14]. This implies
that LT-mediated inhibition might also affect on phagocytosis, an
actin dependent process. Phagocytic function of phagocytes is
important for the clearance of bacteria. This was indicated by
another major virulence factor of B. anthracis, the poly-c-D-
glutamic acid capsule, inhibiting phagocytosis through nonim-
munogenic surfaces, which is critical for full virulence [15]. It has
also been shown that in vivo treatments for LT reduced fluorescent
polystyrene beads engaged with mouse spleen macrophages [16],
and may likely support the suppressive role of LT on
phagocytosis. However, treatment under the same conditions
also suppressed the MEK-C/EBP axis signaling pathways and
induced apoptosis of spleen macrophages [16]. This leads to the
conclusion that an MEK-dependent process is still involved, while
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As the role of LT in the early phases of infection is an important
issue deserving of further investigations [17], it would be
interesting to address the potential pathological role of low dose
LT, by which it would not influence the MEK pathway. As a
result, in this study we sought to investigate the inhibitory role of
low dose LT on phagocytosis. Related issues regarding whether or
not this suppression on phagocytes is beneficial for the survival of
infected bacteria are also discussed.
Results
Various doses of LT affected cell survival, MEK/MAPK
pathways and phagocytosis of macrophage cells
The dosage effect of LT on the suppression of cell viability and
intact MEK1 levels was analyzed using J774A.1 cells (Fig. 1A, B), a
mouse macrophage cell line commonly applied for the study of LT
function [13,18]. We found that the suppression on MEK1 is
associated with the induction of cell death when treated with
various doses of LT (Fig. 1A, 1B; significant suppression in 1.5 and
15 ng/mL LF groups vs. no significant suppression in the other
groups). The phagocytosis of living bacteria Escherichia coli, Bacillus
cereus and Bacillus subtilis, which were used as surrogates as B.
anthracis, were then analyzed under treatments with LT in the
same range of dosage (Fig. 1C, 1D). Our data revealed that LT
significantly suppressed phagocytic activity, regardless of the
bacterium used (Fig. 1C, D), suggesting that such suppression
occurred without strain specificity. Intriguingly, the effective dose
of LT on phagocytosis includes low doses that do not significantly
suppress either cell survival or MEK1 (Fig. 1C and 1D vs. 1A and
1B, 1.5–150 pg/mL LF groups). In addition, MEK1, LT also
blocks other MEKs [19]. To further investigate how LT
treatments influence MAPKs, the downstream of MEKs, we
performed Western blotting analysis (Fig. 1E). Respective gel
densities of the phospho-p38 (pp38) MAPK and the phospho-p42/
44 (pp42/44) MAPK under various treatments are shown (Fig. 1F).
Our data indicated that LT primarily blocked the activation of
p38 MAPK but not the p42/44 MAPK and JNK under treatment
with lipopolysaccharide (LPS) (Fig. 1E, 1F; 1.5 ng/mL LF).
Intriguingly, here we found that the inhibitory dose of LT on
p38 MAPK (Fig. 1E, 1.5 ng/mL LF) was concurrent with the
doses that affect both cell survival (Fig. 1A) and MEK1 (Fig. 1B).
As LPS-induced cytokine production of macrophage was largely
blocked when MAPKs were inactivated [20–21], we found that
the inhibitory dose of LT for TNF-a production (Fig. 1G, 1.5 ng/
mL LF groups) was also consistent with that of the cell viability,
MEK1 and p38MAPK data (Fig. 1A, 1B, 1E, 1.5 ng/mL LF
groups). These results suggest that LT influenced MEK1 and
MEK3/MEK6, the upstream of p38 MAPK, in a similar dose
range in murine macrophages. In addition, such suppression of
phagocytosis could be induced by low dose LT without influencing
the MAPK pathways or cell survival.
Flow cytometry analyses of cell death and phagocytosis
of fluorescent beads
We employed flow cytometry to determine whether LT-treated
c e l l sw e r ea c t u a l l yk i l l e db yt h et o x i n ,a n d ,t h e r e f o r e ,u n a b l et o
phagocytose the bacteria. Through annexin V and propidium
iodide (PI) staining, we found that the LT treatments could only
induce cell death in the 1.5 ng/mL LF groups but not the other
groups treated with lower doses of LT (Fig. 2; 2B vs. 2C, 2D; 2E,
1.5 ng/mL LF groups vs. 1.5–150 pg/mL groups). This is
consistent with our WST-1 data (Fig. 1A, 1.5 ng/mL LF groups),
and further indicates that the suppression of phagocytosis by
lower doses of LT was not likely caused by cell death. In the above
phagocytosis experiments (Fig. 1C, 1D), we measured phagocy-
tosis using a gentamicin protection assay [22–26]. After plating
the macrophage lysate on agar plates, the LT treated groups with
low E. coli counts were considered to exhibit low phagocytosis
activity. Low E. coli counts, however, might be explained by an
enhanced killing of the engulfed E. coli in LT-activated
macrophages rather than a lower uptake of these bacteria, or
alternatively, increased permeability of LT-treated cells to the
antibiotic gentamicin. To confirm the suppressive effect of LT,
fluorescent beads were used as phagocytosis targets and analyzed
using flow cytometry (Fig. 3). Macrophage J774A.1 cells were
allowed to engulf immunoglobulin-opsonized fluorescent beads.
We were able to distinguish the beads from the macrophages
using particle/cell-size differences (Fig. 3A vs. 3C, 3E, 3G; 3I; R1
regions: J774A.1 cells). By differentiating the fluorescent signal of
cells, we were able to measure the beads-phagocytosed phago-
cytes of PA and LT treated groups (Fig. 3F, 3H, 3J, right panels).
Relative phagocytosis was determined by calculating the beads-
phagocytosed/non-phagocytosed ratio of the cell population
(Fig. 3K). We found that treatments using doses higher than
15 pg/mL of LF (with 85 ng/mL PA) significantly reduced the
engulfment on beads (Fig. 3K, * P,0.05, ** P,0.01, 15 pg/mL
LF groups vs. LF untreated groups), which is partly consistent
with our phagocytosis data using living bacteria (Fig. 1C, 1D, 15
and 150 pg/mL LF groups). When the kinase data was also taken
into consideration (Fig. 1B and 1E, no inhibition in 15 and
150 pg/mL LF groups), these results suggested that low dose LT-
mediated suppression on phagocytosis involving a MAPK
independent pathway.
Low plasma levels of LT detected in mice in early stages
of infection
To analyze the effects of low doses of LT on the suppression of
phagocytosis in vivo, we examined the MEK1 level of mouse
splenic mononuclear cells (SMCs) and peripheral blood mono-
nuclear cells (PBMCs) after treatment with LT. Our data revealed
that intravenous LT treatments with doses of 200 and 400 mg/kg,
(but not 50 mg/kg) (LF:PA=15:85) significantly suppressed the
MEK1 level of SMCs and PBMCs of the mice (Fig. 4A). The
corresponding mouse plasma levels of PA and LF within two and
24 hours following treatments with LT (50 mg/kg) are shown
(Fig. 4B). The concentration of LF was much lower than the level
required to suppress MEK1 and MAPK pathways in vitro (Fig. 4B
LF levels: ,1 ng/mL in 2 hr groups, and not detectable [ND] in
24 hr groups vs. Fig. 1B, 1E 1.5 ng/mL groups). Theoretically,
the effective dosage of LT in the early infectious stages is crucial to
the survival of the bacterium. As a result, mouse plasma PA and
LF concentrations in the early stages of infection were also
examined. Mice in the experiment were treated with a lethal dose
of B. anthracis spores (3610
7 CFU/kg; lethality began at 48–
72 hours after the treatment), and the plasma levels of PA and LF
were measured at various points in time. Our data revealed that
during the first 24 hours, PA and LF were not detectable in the
plasma of mice; 48 hours following treatment, only a low level of
PA was barely detectable. The low level of PA and LF detected in
mice during the early stages of the infection was somewhat similar
to a previous report using other experimental animals [27]. Our
data implies that the plasma level of LT in the early stages of
infection was much lower than the MEK1/MAPK suppressive
levels under both in vitro and in vivo conditions (Fig. 1B and 1E
1.5 ng/mL LF groups vs. 4A and 4B 50 mg/kg LT groups vs. 4C
48 hrs groups).
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enhanced mortality in septic mice
According to our results, sub-MEK1 inhibitory doses of LF
(15 pg/mL to 150 pg/mL) plus adequate PA (85 ng/mL) are
sufficient to suppress the macrophage phagocytosis in vitro (Fig. 1C,
1D, 3K). Theoretically, such low doses of LT might be sufficient to
enhance the mortality and bacterial survival in septic mice. As a
result, a septic shock mouse model was employed. First, we
measured the sublethal and lethal doses of E. coli and LT,
respectively. We found that treatment using E. coli at doses higher
than 3.5610
9 CFU/kg, or using LT doses higher than 400 mg/kg
could induce mortality in mice (Fig. 5A, 5B). The LT dose 50 mg/
kg is not only a sublethal dose for mice (Fig. 5B), but also a sub-
MEK1 inhibitory dose of mouse splenic and peripheral blood
mononuclear cells (Fig. 4A, SMCs and PBMCs groups). Notably,
even though sublethal treatments using either E. coli (Fig. 5A,
2610
9 CFU/kg) or LT (Fig. 5B, 50 mg/kg) alone showed no
mortality, and a combination of both treatments resulted in 100%
mortality among the mice (Fig. 5C). In contrast, combined
treatments using vehicle or control protein bovine serum albumin
(BSA) plus E. coli (2610
9 CFU/kg) did not lead to mortality
(Fig. 5C). To investigate the inhibitory role of sub-MEK1 dose of
LT (Fig. 4A, 50 mg/kg) on the bacterial clearance in vivo, viable
bacteria (CFU) in mouse blood specimens were analyzed after
combined treatment with LT and E. coli for 2, 16 and 24 hours
(Fig. 5D). The control mice treated with BSA significantly
eliminated bacteria from their circulation within 24 hours, while
LT-treated mice showed no obvious clearance during the same
period, as evidenced by the 4–6 fold higher levels of residual
surviving bacteria in their circulation (Fig. 5D, LT vs. BSA groups;
* P,0.05, ** P,0.01). These findings suggested that LT-mediated
suppression with a sub-MEK1 inhibitory dose of splenic and
peripheral blood mononuclear cells is sufficiently beneficial for
bacteria to survive host clearance.
Discussion
Phagocytosis is a process relying highly on actin cytoskeletal
dynamics [28]. Specific mechanisms that block actin dynamics, in
so doing suppress phagocytic uptake into macrophages. Such
mechanisms are evolved by various pathogens to avoid robust
bactericidal effector functions [29]. Given that the MEK/MAPK
pathways play an important role in the regulation of cytoskeletal
dynamics [30], and that LT, an MEK inhibitor, could block actin
dynamics [14,31], it is not surprising to observe the inhibitory role
of LT on phagocytosis. However, whether or not there involves a
MAPK-independent pathway in LT-mediated suppression on
phagocytosis, is not clearly demonstrated. Intriguingly, our data
suggested that such inhibitory pathways are likely to exist.
Using a cell culture model, here we find that LT could suppress
the phagocytosis of J774A.1 macrophage cells at low doses without
influencing the MAPK pathways (Fig. 1C, 1D and 3K; 15 pg/mL
groups). A septic shock mouse model revealed that the anti-
phagocytic properties of LT could exacerbate the bacterial
clearance and enhance mortality in mice (Fig. 5C). Enhanced
mortality in septic animal after LT treatment is to a certain degree
consistent with a previous study [32]. These authors shed light on
the anti-inflammatory role of LT on the amelioration of LPS
treatment in mice, while the exacerbation of LT on E. coli treated
mice, however, was not specifically linked to the suppression of
macrophage phagocytosis [32]. Our data provides an alternative
Figure 2. Flow cytometry analysis for LT-induced cell death of
macrophage cells. Flow cytometry analysis was employed to
determine the cell death of macrophage cells (A–D). After 3-hour
treatments of various concentrations of LT, mouse macrophage J774A.1
cells were stained with annexin V-APC and PI. The upper right
quadrants (Rl) and the lower right quadrants (R2) were positive for PI
uptake representing the non-viable cells (A–D). One representative
diagram out of three experiments is showed, in which the percentage
of cells in each quadrant was indicated (A–D). The quantitative results of
relative dead cells (% of cell subpopulations in R1 + R2) are presented as
mean 6 standard deviation (E). ** P,0.01, compared to the PA control
groups (LF untreated).
doi:10.1371/journal.pone.0014289.g002
Figure 1. LT-mediated suppression of macrophage cells. Inhibitory effects of various concentrations of LT treatments (3 hours) on cell viability
(A), intact MEK1 levels (B), phagocytosis of E. coli (C), B. cereus and B. subtilis (D), MAPK pathways (E, F) and TNF-a production (G) of mouse
macrophage J774A.1 cells are shown. The numbers of surviving cells (A) and surviving bacteria after phagocytosis (C, D) in the PA groups (LF
untreated) were adjusted to 100%. Levels of pp38, p38, pp42/44, p42/44 MAPKs in J774A.1 cells treated with LPS and LT were analyzed by Western
blotting (E). Phosphorylated c-Jun (p-c-Jun) levels revealed JNK activity in J774A.1 cells (E). Quantitative results of pp42/44 and pp38 levels were
obtained by measuring gel intensity normalized with internal controls p42/44 and p38, respectively (F); the levels in the PA groups (LF untreated)
were adjusted to 100%. After various PA, LT and LPS treatments, the level of TNF-a secreted by J774A.1 cells was determined by ELISA (G); PA groups
(without LF and LPS treatment) were adjusted to 100%. Error bars indicate standard deviations. * P,0.05, ** P,0.01, *** P,0.001 compared to the PA
controls (PA: 85 ng/mL). n=6 (3 experiments with 2 replicates) (A, C, D, G).
doi:10.1371/journal.pone.0014289.g001
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fluorescent beads by macrophages (A–J). The time course of LT and PA treatments was 3 hours. In panels A, C, E, G, I, the X-axis represents particle/
cell size (forward scatter) and the Y-axis represents the granularity of cells (side scatter). A and B: fluorescent beads only, C and D: macrophage cells
only, E and F: beads + PA (85 ng/mL) treated cells, G and H: beads + LT (LF 150 pg/mL + PA 85 ng/mL) treated cells, I and J: beads + LT (LF 15 pg/mL
+ PA 85 ng/mL) treated cells. One representative diagram out of three experiments is shown (A–J). The R1 region in panels A, C, E, G and I reveals the
population of the macrophage, which was specifically gated to obtain the graphs B, D, F, H, J, respectively. In panels B, D, F, H, J, the X-axis represents
fluorescent intensity, which indicates the levels of macrophage-engaged beads, and the Y-axis represents the granularity of the cells (side scatter).
Anthrax LT on Phagocytosis
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suppression of phagocytosis by LT, because LT greatly reduced
bacterial clearance (Fig. 5D). Because we used low doses of LT
without influencing the MEK1 of splenic and peripheral blood
mononuclear cells (Fig. 4A, 50 mg/kg LT groups), the MEK-
dependent suppression on bactericidal superoxide [12] is not likely
to be involved. Because phagocytic cells play an important roles in
the cross road of innate immunity and adaptive immunity [33],
our findings may broaden our current understanding of the
immunosuppressive properties of LT. It is well known that LT
paralyzes the immune system primarily mediated through the
inhibition of MEK/MAPK pathways, and in part mediated
through the initiation of leukocyte cell death [5,17,34]. Intrigu-
ingly, here we found that the phagocytic inhibitory doses of LT
could be far lower than that of eliciting cell death of phagocytes
(Fig. 1A, 2E vs. 1C, 1D, 3K), and that such inhibition did not
significantly influence the MEK/MAPK pathways (Fig. 1B, 1E, vs.
1C, 1D, 3K). A reasonable speculation is that the immunosup-
pressive effect of LT might be initiated at a relatively earlier
infectious stage, in which LT is produced at low doses.
Accordingly, here we proposed a hypothetical model (Fig. 6).
During the early infections, B. anthracis expressed low levels of LT
that are insufficient to suppress the MEK pathway of phagocytes
(Fig. 4A, 4C), but critical for the inhibition of phagocytic clearance
of bacterial pathogens (Fig. 5D; 6A–C). After B. anthracis is
amplified to a greater population in the host (Fig. 6D), the LT
gradually reached to an MEK/MAPK inhibitory dose (Fig. 6E)
and finally led to the suppression of MEK/MAPK and cell death
of macrophages (Fig. 6F). The molecular target of LT under such
low doses, however, requires further investigation.
One of the candidate pathways is through NALP1. It has been
shown that the susceptibility of different mouse strains is linked to
the polymorphic locus Nalp1b [35]. The product of this locus,
NALP1, is a component of inflammasone, a protein complex
consisting of NALP1 and caspases 1, leading to the processing and
release of pro-inflammatory cytokines IL-1b and IL-18 [36].
Activation of caspase-1 by NALP1 mediates murine macrophage
cytolysis through the mitochondrial protein Bnip3 and Bnip3L
[35,37]. Because MEK cleavage occurs in both resistant and
susceptible cells [13,38], but NALP1 activation occurs in
susceptible macrophages only [35], these evidences suggest that
LT-mediated NALP1 suppression might be independent of MEK
pathways. However, NALP1 is linked to LT-mediated suppres-
sion of other cellular functions, while the phagocytosis has not
been characterized in these studies. As a result, it may be
suggested that NALP1 or ayet unidentified pathway isresponsible
for the suppression of phagocytosis by low dose LT. Further
investigations are required to characterize the specific pathways
involved.
In summary, here we demonstrated that LT suppresses
macrophage phagocytosis through both MEK/MAPK dependent
and independent pathways. Our results suggest that a two-step
inhibition of macrophage phagocytosis by LT. The first stage
involved a MEK-independent inhibition when the LT concentra-
tion was lower than the MEK/MAPK suppressive dosage (Fig. 6B).
In this stage, LT suppresses macrophage phagocytosis and
Figure 4. Leukocyte MEK1 levels and plasma LT levels in LT
treated mice. After mice were treated with various doses (50, 200 and
400 mg/kg) of LT intravenously for 3 hours, intact MEK1 levels of mouse
splenic mononuclear cells (SMCs) and peripheral blood mononuclear
cells (PBMCs) were analyzed using Western blotting (A). Cellular actin
levels were used as internal controls of respective groups (A). The
relative gel densities after being normalized with respective actin levels
are shown; the level of untreated groups was adjusted to 100% (A). The
plasma PA and LF levels were determined using ELISA from specimens
of mice treated with LT (50 mg/kg, a sublethal dose) (B), or spores of B.
anthracis (3610
7 CFU/kg, a lethal dose) (C). ND: not detectable. n=6 (3
experiments with 2 replicates) (B, 2 hr groups; C). n=10 (3 experiments
with 3 or 4 replicates) (B, 24 hr groups).
doi:10.1371/journal.pone.0014289.g004
The percentage of the cells with relatively high fluorescence intensity on the right panels of B, D, F, H, J, indicated the phagocytosed levels of beads
by macrophages. In contrast, the percentage of cells on the left panels with relatively low fluorescence intensity indicates the number of cells without
phagocytosed beads (B, D, F, H, J). The relative phagocytosis of macrophages was quantified by calculating the beads-phagocytosed (right panel: R)/
non-phagocytosed (left panel: L) ratio of macrophages (K), the level of LF untreated (PA only) groups were normalized to 100%. The F, H, J labels in
the columns of Fig. 3K indicate the respective conditions as showed in Fig. 3F, 3H and 3J, respectively (K). Error bars indicate standard deviations of
three experiments. * P,0.05, ** P,0.01 compared to the PA (LF untreated) control groups. n=6 (3 experiments with 2 replicates).
doi:10.1371/journal.pone.0014289.g003
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Because anthrax can cause massive bacteremia [34], in the second
stage, LT might progressively increase and eventually reach an
MEK/MAPK suppressive dose, thereby leading to a p38 MAPK
dependent inhibition (Fig. 6D-F). Our results suggest that LT is
able to transmit a phagocytic suppressive signal through an MEK/
MAPK independent pathway, which could be beneficial for the
survival of B. anthracis during early infectious stages.
Materials and Methods
Ethics Statement
The research methods applied regarding the experimental mice
were approved by the Animal Care and Use Committee of Tzu
Chi University (approval ID: 95017 and 98104).
Mice, bacteria and toxin
The C57BL/6J mice (males, 8-11 weeks of age) were
purchased from National Laboratory Animal Center (NLAC,
Taipei, Taiwan). Mice were housed in the Laboratory Animal
Center of Tzu Chi University (Hualien, Taiwan). B. anthracis
(ATCC 14186), which contains both pXO1 and pXO2 plasmids
that express functional lethal toxin (LT) and edema toxin (ET),
was grown and maintained as previously described [18,39].
Native B. anthracis lethal toxins, PA and LF, were purified from
the culture supernatants of B. anthracis (ATCC 14186). The
bacteria E. coli (OP50, a laboratory strain [40–41]), B. cereus
(ATCC 7004) and B. subtilis (ATCC 21336) were used in the
phagocytosis experiments.
Figure 5. Treatment with sublethal doses of LT enhanced mortality and impaired bacterial clearance in mice with bacteremia. To
test the sublethal dose of LT, mortality in C57BL/6J mice was measured after treatment with different doses of E. coli (A, n=8) or LT (B, n=8) (4
experiments with 2 replicates). The mortality of mice with E. coli bacteremia could be enhanced by sub-MAPK LT treatments (50 mg/kg), but not by
equivalent quantities of control protein BSA or vehicle treatments (C, n=8) (4 experiments with 2 replicates). The surviving E. coli in the plasma of the
septic mice was enhanced by the treatment of sublethal doses of LT (50 mg/kg) (D, n=6) (3 experiments with 2 replicates). The
{ marks shown in A
and B indicates the dosages of E. coli and LT that used in C and D. * P,0.05, ** P,0.01.
doi:10.1371/journal.pone.0014289.g005
Figure 6. A hypothetical model. In the early infectious stage of B.
anthracis (A), LT likely suppresses phagocytosis at a low level resulting
in an increase in bacterial survival and decrease in host clearance
without influencing the MEK/MAPK pathways (B–C). As the surviving
bacteria accumulated to a high level (D), the LT level may gradually
reach to a MAPK inhibitory dose (E) leading to further disruption of host
homeostasis and immune responses (F). Q Activation processes. H
Inhibition processes.
doi:10.1371/journal.pone.0014289.g006
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The mouse macrophage-like cell line J774A.1 (ATCC TIB67)
was maintained in Dulbeco’s modified Eagle’s medium (DMEM)
containing 10% fetal bovine serum (FBS) used in cytotoxicity
analysis [18,26]. After being changed with serum free medium,
cells (1610
5/well) were treated with different concentrations
(0.15 fg/mL to 15 ng/mL) of LF plus 85 ng/mL PA in a 96-
well cell culture dish. Three hours after treatments, the level of
viable cells was analyzed using the WST-1 kit (Roche Diagnostics,
Taipei, Taiwan) according to the manufacturer’s instructions
[26,42–43]. The assay principle was based on a reduction of the
tetrazolium salt WST-1 to formazan by cellular dehydrogenases in
viable cells. The generation of yellow formazan was measurable at
450 nm and was correlated to the number of cells. A standard
curve plotted between WST-1 values with serious diluted J774A.1
cells (0 to 5610
5) was obtained first, and the relative number of
viable cells was then calculated, accordingly.
Phagocytosis analysis by gentamicin protection assay
Gentamicin protection assay were performed as described in
previous literatures [24–25,44–45]. Live bacteria E. coli, B. cereus
and B. subtilis (1610
8 CFU/mL in serum free cell culture medium;
1 mL/reaction) were incubated with J774A.1 cells (1610
8/well,
with or without one hour LT pretreatment) in an antibiotic free
condition. After 90-minutes of incubation, a cell membrane
impermeable antibiotic gentamicin (10 mg/mL) was added to the
medium for 30 minutes to eliminate the extracellular bacteria.
Macrophage cells containing engulfed bacteria were washed with
16phosphate-buffered saline (PBS), and lysed in 1% Triton-X
100, 16PBS solution. The cell lysate was then plated on LB agar
plates to determine the number of living bacteria (CFU) engulfed
by macrophages.
Analyses of MEK/MAPK pathways
For in vivo analysis, C57BL/6J mice were intravenously treated
with various dosages of LT (50, 200, 400 mg/kg body weight,
LF:PA=15:85). Three hours after treatment, the splenic and
peripheral mononuclear cells were isolated and purified using a
Ficoll-Paque PLUS kit (GE healthcare, Singapore, Singapore)
according to the manufacturers’ instructions. The cell lysate was
then subjected to MEK1 analysis, as indicated in the following
methods. For in vitro analysis, J774A.1 cells (1610
6/well) were
cultured on six-well dishes treated with various concentrations of
LT for three hours with or without lipopolysaccharide (LPS,
0.1 mg/mL, Sigma-Aldrich, St. Louis, MO, USA) [39]. PA
treatments (100 ng/mL) were used as negative controls. Cell
lysate was separated by SDS-PAGE and then transferred to a
nitrocellulose paper, whereupon Western blotting analysis was
performed, as previously described [39]. The levels of MEK1 were
measured by specific antibody (anti-NH2-terminal MEK1, Upstate
Biotechnology, Lake Placid, NY, USA). The cellular MAPKs were
measured by probing the antibodies against MAPK pathway
kinases (p42/44, phospho-p42/44 [pp42/44], p38, and phospho-
Jun kinase (JNK), Cell Signaling Technology, Danvers, MA; anti-
pp38 Promega, Madison WI, USA). Jun kinase activity was
measured by phosphorylation of c-Jun using a kit (Cell Signaling
Technology, Danvers, MA, USA). The intensity of the blots was
measured using Image J (version 1.32; National Institutes of
Health, USA) software.
Analysis of TNF-a production
Macrophage J774A.1 cells (2610
5) were treated with 0.1 mg/
mL LPS and various concentrations of LT for three hours, in 96-
well dishes. The cell culture medium was then collected from each
well. The TNF-a levels produced by macrophage cells was
determined using an enzyme-linked immunosorbent assay (ELISA)
kit from eBioscience, (San Diego, CA, USA) according to the
manufacturer’s instructions.
Phagocytosis analysis by flow cytometry
Phagocytosis analysis using fluorescent beads by flow cytometry
was modified from previously described methods [16,46–47].
Silica beads (mean diameter 1.1 mm, Bangs Laboratories, Fishers,
IN, USA) [48] were opsonized with fluorescein-labeled rat anti-
mouse immunoglobulin (Ig, 1 mg/mL, Jackson ImmunoResearch
Laboratories) for 30 min at room temperature (25uC) in 16PBS.
After blocking with 5% bovine serum albumin (BSA) in 16PBS for
one hour, the beads (1610
7) were mixed with J774A.1 cells
(1610
6, with or without one hour LT pretreatment) in 200 mL
cell-culture medium. After two washes (PBS-albumin, 300 g,
10 min, 25uC), and fixation (2% paraformaldehyde in PBS,
30 min) the levels of phagocytosis were revealed by the florescent
intensity of cell-engulfed beads, and could be identified using
fluorescence flow cytometry (FACScalibur, BD Biosciences). Beads
were distinguished from the J774A.1 cells according to their
forward and side scatter characteristics (Fig. 3A vs. 3C; R1 region:
J774A.1 cells). We then analyzed the fluorescent signals (beads)
from the R1 regions (J774A.1 cells) to identify the relative level of
phagocytosis (Fig. 3B, 3D, 3F, 3H, 3J, right panels). The J774A.1
cells were gated and 10,000 events acquired for each sample. The
background fluorescence (,5%) was used to set the [left (L)/right
(R)] border lines in Fig. 3B, 3D, 3F, 3H and 3J by beads-untreated
J774A.1 cells. The level of phagocytosis/non-phagocytosis ratio in
the beads was normalized to 100% by PA treated (LF untreated)
J774A.1 cells. To avoid inefficient binding to cellular receptors
[49], all LT treatments were supplied at the same doses levels as
PA (85 ng/mL).
Cell death analysis by flow cytometry
Following the previously described method [50], the dead cell
subpopulations was determined by staining the cells with
allophycocyanin (APC) conjugated annexin V (annexin V-APC)
and propidium iodide (PI). The macrophage J774A.1 cells were
treated with PA or various doses of LT for 3 hours. After the
treatments, the total number of cells (5610
5 per sample) was
washed twice with PBS for staining. The cells were stained by
annexin V-APC (0.5 mg/ml) and PI (2 mg/ml) in the staining
buffer (10 mM HEPES [4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid], pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2,
1.8 mM CaCl2) at room temperature for 20 min in the dark. After
labeling, the cells were diluted in 10 mM HEPES buffer to a final
volume of 600 ml, and analyzed by flow cytometry.
ELISA analysis for circulating LT in mouse plasma
A sandwich ELISA modified from previously described methods
[27] was performed. To investigate the turnover of LT in the
blood circulation, mice were treated with 50 mg/kg body weight
LT (LF:PA=15:85). Blood specimens were collected from the
mice 2 hours and 24 hours after the treatment, and mixed with
the anticoagulant acid citrate dextrose (5:1) (ACD: 20 mmol/L
citric acid, 110 mol/L sodium citrate, and 5 mmol/L glucose;
pH 7.3) to avoid blood clotting. Anti-PA and anti-LF antibodies
were purified with serum from rabbits and mice immunized with
high-performance liquid chromatography (HPLC)-purified PA or
LF (6 cycles at 3-week intervals; 100 mg each cycle) as previously
described [39]. Protein A column-purified polyclonal rabbit anti-
PA or anti-LF antibodies (50 ml, 40 mg/ml) were incubated
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U.S.A.) at 4uC. The plates were then blocked with 5% bovine
serum albumin (BSA; Sigma)/PBS for 2 h at room temperature.
The plates were washed three times with 0.5% Tween 20-16PBS
and once with 16PBS. To establish the standard cures, quantified
(HPLC-purified B. anthracis-derived) native PA and LF were
diluted with mouse serum at 1 mg/ml and serially diluted onto the
ELISA plate. To detect PA and LF in blood of infected animals,
serum was added to the plate initially diluted 1:1 in 5% BSA-PBS,
and serially diluted across the plate. After one-hr incubation, the
plates were washed as described above. Protein A column-purified
mouse anti-PA or anti-LF polyclonal antibodies were diluted
1:1000 in 5% BSA-PBS and added to the plate for one-hr of
incubation. The plate was then washed again, followed by the
addition of goat anti-mouse immunoglobulin G (IgG) (diluted in
5% BSA-PBS). After one hour of incubation and two washes
(PBS), donkey anti-goat horseradish peroxidase (HRP) conjugate
(minimal cross-reactivity to mouse and rabbit IgGs, Jackson
ImmunoResearch Laboratories, West Grove, PA, USA) was
diluted in 5% BSA-PBS and incubated for additional one hour.
ELISA reactions were developed with the substrate o-phenylene-
diamine (OPD) (Sigma). Experiments were run in triplicate,
averaging each data point with standard deviation.
Septic shock mouse model
Following the previously described method [51], fresh E. coli
culture was collected when the OD reached 0.4–0.5. Using a
predetermined standard curve [51], we adjusted the E. coli
suspension to 2610
7 CFU/mL in normal saline. C57BL/6J mice
received sequential intravenous treatments of E. coli (2610
9 to
5610
9 CFU/kg) and LT (50 mg/kg to 400 mg/kg). The mortality
of the mice was recorded, and blood specimens were collected
from the mice subjected to combined treatments of E. coli
(2610
9 CFU/kg) and LT (50 mg/kg) at 2, 16, and 24 hours.
Because mortality occurred within 24 hours (Fig. 5C, day1
groups), the data of the LT-treated 24 hour groups (Fig. 5D, LT
+ E. coli, 24 hr groups), was obtained from the survivors. Blood
samples were mixed with anticoagulant ACD (2:1), and the blood/
ACD mixture (15 ml) was applied directly to LB agar plates. The
number of cells formed in the colony after an overnight culture
was recorded.
Statistical analysis
All results were calculated from data of no fewer than three
independent experiments. Statistical differences between groups
were calculated using Student t test and presented as mean 6
standard deviation (SD). A P value of less than 0.05 (P,0.05) was
considered statistically significant. The statistical tests were carried
out and output to graphs using Microsoft Excel (Microsoft
Taiwan, Taipei, Taiwan) and SigmaPlot (Systat Software, Point
Richmond, CA, USA) software.
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